Skip to content
Companies

Cime Therapeutics

Shielded stem cells for blood disease transplants

Raised to date

$2.1M

of $2.5M offered across 1 Form D filing

Still open
$400K
Investors
3
Last filed
Mar 21, 2025

About

Cimeio Therapeutics is a pioneering biotechnology company established in 2020, committed to revolutionizing the treatment landscape for hematologic diseases through innovative cell therapies. The company focuses on addressing the limitations posed by traditional hematopoietic stem cell (HSC) transplantation, particularly the challenges of harsh conditioning regimens and restricted eligibility for patients.

Cimeio stands out with its unique Shielded-Cell & Immunotherapy Pairs™ platform, which enhances the safety and accessibility of HSC transplants while minimizing the risks inherent to conventional treatments.

Funding

  • Option to acquireFiled Mar 21, 2025Form D
    $2.1M/ $2.5M

Product

Shielded-Cell & Immunotherapy Pairs™ (SCIP) platform

Cell Therapy

The SCIP platform is an innovative technology that develops modified variants of cell surface proteins in hematopoietic stem cells (HSCs). These modifications allow the cells to maintain their essential functions while resisting depletion from immunotherapies. Furthermore, the platform features paired immunotherapies that selectively target and deplete diseased cells, ensuring that the shielded healthy cells remain unharmed.

  • Modification of cell surface proteins in HSCs for enhanced therapy resilience
  • Selective depletion of diseased cells while protecting healthy cells
  • Versatile applications across various medical conditions, including genetic diseases and hematologic malignancies

Built for

Hospitals, clinics, and research institutions specializing in stem cell transplantation

People on file